Face-Off by CancerNetwork® is not your typical oncology discussion—it’s a high-energy, head-to-head showdown where top cancer institutions debate the latest breakthroughs in a debate. With a mix of friendly competition, expert insights, and a touch of humor, Face-Off makes complex data exciting and engaging. Designed for fellows, junior oncologists, and key stakeholders, this lively program turns learning into an interactive experience that’s as entertaining as it is educational!
FACE-OFF: Team Blue vs Team Purple
December 18th 2024Amer Zeidan, MBBS; Catherine Lai, MD; Bart Scott, MD; Andrew Brunner, MD; Jonathan Abbas, MD; Akriti Jain, MD; Mohamed Hegazi, MD; Somedeb Ball, MBBS; and Salman Fazal, MD, examine critical clinical decisions in myelodysplastic syndrome management, including optimal sequencing of erythropoiesis-stimulating agents vs luspatercept, dosing strategies, and efficacy data from pivotal trials such as MEDALIST, IMerge, and ELEMENT-MDS, which demonstrate improvements in transfusion burden and hemoglobin levels.
Precision Oncology in AML: Molecular Insights, Maintenance Strategies, and Emerging Therapies
December 18th 2024Panelists discuss how emerging therapies like CC-486, venetoclax, and menin inhibitors are reshaping treatment strategies for relapsed and refractory acute myeloid leukemia while debating the role of posttransplant maintenance and personalized approaches based on genetic mutations such as NPM1 and TP53.
Bispecifics, Sequencing, and Beyond: A Multiple Myeloma Face-Off
October 28th 2024Experts examine diverse aspects of bispecific antibody therapies in relapsed/refractory multiple myeloma, including clinical trial results, combination strategies, dosing considerations, sequencing with CAR T-cell therapy, prophylactic measures, outpatient administration, and implementation in community settings, to optimize patient outcomes and treatment approaches.
Team Blue vs Team Green: Treatment Strategies in Relapsed Refractory Multiple Myeloma
October 25th 2024Experts examine cutting-edge treatments, clinical trial results, and personalized approaches for managing relapsed/refractory multiple myeloma, focusing on novel therapies like CAR T-cells, bispecific antibodies, and their optimal sequencing to improve patient outcomes.